Literature DB >> 74254

The synthesis and antitumor activity of arabinosyl-5-azacytosine.

J A Beisler, M M Abbasi, J S Driscoll.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1977        PMID： 74254     DOI： 10.1016/0006-2952(77)90463-4

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN： 0006-2952            Impact factor:   5.858


× No keyword cloud information.
  7 in total

Review 1.  Arabinosyl-5-azacytosine: a novel nucleoside entering clinical trials.

Authors:  J L Grem; D D Shoemaker; D F Hoth; S A King; J Plowman; D Zaharko; C K Grieshaber; S D Harrison; J C Cradock; B Leyland-Jones
Journal:  Invest New Drugs       Date:  1987-12       Impact factor: 3.850

2.  Phase II study of fazarabine (NSC 281272) in patients with metastatic colon cancer.

Authors:  N Ben-Baruch; A M Denicoff; B R Goldspiel; J A O'Shaughnessy; K H Cowan
Journal:  Invest New Drugs       Date:  1993-02       Impact factor: 3.850

3.  Phase II trial of fazarabine (arabinofuranosyl-5-azacytidine) in patients with advanced pancreatic adenocarcinoma.

Authors:  E S Casper; G K Schwartz; D P Kelsen
Journal:  Invest New Drugs       Date:  1992-08       Impact factor: 3.850

4.  Comparison of the activity of arabinosyl-5-azacytosine, arabinosyl cytosine, and 5-azacytidine against intracerebrally implanted L1210 leukemia.

Authors:  J S Driscoll; D G Johns; J Plowman
Journal:  Invest New Drugs       Date:  1985       Impact factor: 3.850

5.  Phase II trial of fazarabine (ARA-AC, arabinosyl-5-azacytosine) in metastatic breast cancer.

Authors:  R S Walters; R L Theriault; F A Holmes; G N Hortobagyi; L Esparza
Journal:  Invest New Drugs       Date:  1992-04       Impact factor: 3.850

6.  Phase I trial of a 72-h continuous-infusion schedule of fazarabine.

Authors:  R Amato; D Ho; S Schmidt; I H Krakoff; M Raber
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

7.  Arabinofuranosyl-5-azacytosine: activity against human tumors in athymic mice.

Authors:  R E Wallace; D Lindh; F E Durr
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.